Molecular diagnosis of antimicrobial resistance in Escherichia coli

References

• O’Neill J. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. London, 2014. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• World Health Organization (WHO). global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva, 2017. Available from: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/
   Google Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288–1301.
   PubMed Web of Science ®Google Scholar
• Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Antimicrobial resistance trends of escherichia coli bloodstream isolates: A population-based study, 1998-2007. J Antimicrob Chemother. 2009 Jul;64(1):169–174.
   PubMed Web of Science ®Google Scholar
• Sogaard M, Norgaard M, Dethlefsen C, et al. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: A population-based cohort study. Clin Infect Dis. 2011 Jan 1;52(1):61–69.
   PubMed Web of Science ®Google Scholar
• Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013 Aug 29;369(9):840–851.
   PubMed Web of Science ®Google Scholar
• Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis. 2003 Jul 1;37(1):50–58.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012 May 31;366(22):2055–2064.
   PubMed Web of Science ®Google Scholar
• Ku LC, Boggess KA, Cohen-Wolkowiez M. Bacterial meningitis in the infant. Clin Perinatol. 2014 Dec 6;42(1):29–45.
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. N Engl J Med. 1993 Jun 24;328(25):1821–1827.
   PubMed Web of Science ®Google Scholar
• Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis. 2001 Jun 15;32(12):1706–1709.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother. 2004 Jun;53(Suppl 2):ii29–36.
   PubMedGoogle Scholar
• Hilborn ED, Mermin JH, Mshar PA, et al. A multistate outbreak of escherichia coli O157: h7infections associated with consumption of mesclun lettuce. Arch Intern Med. 1999 Aug 9–23;159(15):1758–1764.
   PubMedGoogle Scholar
• Tadesse DA, Zhao S, Tong E, et al. Antimicrobial drug resistance in escherichia coli from humans and food animals, united states, 1950-2002. Emerg Infect Dis. 2012 May;18(5):741–749.
   PubMed Web of Science ®Google Scholar
• Erb A, Sturmer T, Marre R, et al. Prevalence of antibiotic resistance in escherichia coli: overview of geographical, temporal, and methodological variations. Eur J Clin Microbiol Infect Dis. 2007 Feb;26(2):83–90.
   PubMed Web of Science ®Google Scholar
• Von Baum H, Marre R. Antimicrobial resistance of escherichia coli and therapeutic implications. Int J Med Microbiol. 2005 Oct;295(6–7):503–511.
   PubMed Web of Science ®Google Scholar
• Jean SS, Hsueh PR. High burden of antimicrobial resistance in asia. Int J Antimicrob Agents. 2011 Apr;37(4):291–295.
   PubMed Web of Science ®Google Scholar
• Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in delhi, india: A cohort study. Lancet Glob Health. 2016 Oct;4(10):e752–e760.
   PubMed Web of Science ®Google Scholar
• Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the asia-pacific region: data from the study for monitoring antimicrobial resistance trends (SMART) program, 2007. Antimicrob Agents Chemother. 2009 Aug;53(8):3280–3284.
   PubMed Web of Science ®Google Scholar
• Talan DA, Takhar SS, Krishnadasan A, et al. Fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing escherichia coli infections in patients with pyelonephritis, united states(1). Emerg Infect Dis. 2016 Sep;22(9). DOI:10.3201/eid2209.160148.
   PubMed Web of Science ®Google Scholar
• Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.
   PubMedGoogle Scholar
• Bryce A, Hay AD, Lane IF, et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. Bmj. 2016 Mar;15(352):i939.
   Google Scholar
• Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006 Oct;9(5):466–475.
   PubMed Web of Science ®Google Scholar
• Stoesser N, Sheppard AE, Pankhurst L, et al. Evolutionary history of the global emergence of the escherichia coli epidemic clone ST131. MBio. 2016 Mar 22;7(2):e02162–15.
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant enterobacteriaceae. Clin Microbiol Rev. 2015 Jul;28(3):565–591.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Porter S, Thuras P, et al. Epidemic emergence in the united states of escherichia coli sequence type 131-H30 (ST131-H30), 2000 to 2009. Antimicrob Agents Chemother. 2017 Jul 25;61(8). DOI:10.1128/AAC.00732,17
   Web of Science ®Google Scholar
• Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015 Jan;13(1):42–51.
   PubMed Web of Science ®Google Scholar
• Patel J, Richter S. Mechanisms of resistance to antibacterial agents. In: Jorgensen J, Pfaller M, Carroll K, et al., editors. Manual of clinical microbiology. 11th ed. Washington (DC): ASM Press; 2015. p. 1212.
   Google Scholar
• Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat. 2001. 4. Apr(2):106–117.
   Google Scholar
• Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010 Dec;13(6):151–171.
   PubMed Web of Science ®Google Scholar
• Rosenberg EY, Ma D, Nikaido H. AcrD of escherichia coli is an aminoglycoside efflux pump. J Bacteriol. 2000 Mar;182(6):1754–1756.
   PubMed Web of Science ®Google Scholar
• Aires JR, Nikaido H. Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of escherichia coli. J Bacteriol. 2005 Mar;187(6):1923–1929.
   PubMed Web of Science ®Google Scholar
• Yang J, Ye L, Wang W, et al. Diverse prevalence of 16S rRNA methylase genes armA and rmtB amongst clinical multidrug-resistant escherichia coli and klebsiella pneumoniae isolates. Int J Antimicrob Agents. 2011 Oct;38(4):348–351.
   PubMed Web of Science ®Google Scholar
• Bajaj P, Singh NS, Virdi JS. Escherichia coli beta-lactamases: what really matters. Front Microbiol. 2016 Mar;30(7):417.
   Google Scholar
• Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321–331.
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010 Mar;54(3):969–976.
   PubMed Web of Science ®Google Scholar
• Walsh TR, Toleman MA, Poirel L, et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005 Apr;18(2):306–325.
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005 Jan 27;352(4):380–391.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009 Jan;22(1):161.
   PubMed Web of Science ®Google Scholar
• Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012 Jul;67(7):1597–1606.
   PubMed Web of Science ®Google Scholar
• Conrad S, Oethinger M, Kaifel K, et al. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of escherichia coli. J Antimicrob Chemother. 1996 Sep;38(3):443–455.
   PubMed Web of Science ®Google Scholar
• Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2003 Oct;47(10):3222–3232.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005 Jul 15;41(Suppl 2):S120–6.
   PubMed Web of Science ®Google Scholar
• Friedman SM, Lu T, Drlica K. Mutation in the DNA gyrase A gene of escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother. 2001 Aug;45(8):2378–2380.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Bogaki M, Nakamura M, et al. Quinolone resistance-determining region in the DNA gyrase gyrA gene of escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272.
   PubMed Web of Science ®Google Scholar
• Oram M, Fisher LM. 4-quinolone resistance mutations in the DNA gyrase of escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother. 1991 Feb;35(2):387–389.
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999;58(Suppl 2):11–18.
   PubMed Web of Science ®Google Scholar
• Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of escherichia coli multiple-antibiotic-resistance (mar) mutants. J Bacteriol. 1996 Jan;178(1):306–308.
   PubMed Web of Science ®Google Scholar
• Oethinger M, Kern WV, Jellen-Ritter AS, et al. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother. 2000 Jan;44(1):10–13.
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005 Jul;56(1):20–51.
   PubMed Web of Science ®Google Scholar
• Cattoir V, Nordmann P. Plasmid-mediated quinolone resistance in gram-negative bacterial species: an update. Curr Med Chem. 2009;16(8):1028–1046.
   PubMed Web of Science ®Google Scholar
• Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006 Oct;6(10):629–640.
   PubMed Web of Science ®Google Scholar
• Poirel L, Pitout JD, Calvo L, et al. In vivo selection of fluoroquinolone-resistant escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob Agents Chemother. 2006 Apr;50(4):1525–1527.
   PubMed Web of Science ®Google Scholar
• Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5638–5642.
   PubMed Web of Science ®Google Scholar
• Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5. DOI:10.3389/fmicb.2014.00643.
   PubMed Web of Science ®Google Scholar
• Li XZ, Plesiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in gram-negative bacteria. Clin Microbiol Rev. 2015 Apr;28(2):337–418.
   PubMed Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in china: A microbiological and molecular biological study. Lancet Infect Dis. 2016 Feb;16(2):161–168.
   PubMed Web of Science ®Google Scholar
• Baron S, Hadjadj L, Rolain JM, et al. Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents. 2016 Dec;48(6):583–591.
   PubMed Web of Science ®Google Scholar
• Gao R, Hu Y, Li Z, et al. Dissemination and mechanism for the MCR-1 colistin resistance. PLoS Pathog. 2016 Nov 28;12(11):e1005957.
   PubMed Web of Science ®Google Scholar
• Xavier BB, Lammens C, Ruhal R, et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in escherichia coli, belgium, june 2016. Euro Surveill. 2016 Jul 7;21(27). DOI:10.2807/1560,7917.ES.2016.21.27.30280
   PubMedGoogle Scholar
• Skold O. Resistance to trimethoprim and sulfonamides. Vet Res. 2001 May-Aug;32(3–4):261–273.
   PubMed Web of Science ®Google Scholar
• Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001 Jun 1;32(11):1608–1614.
   PubMed Web of Science ®Google Scholar
• Skold O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updat. 2000 Jun;3(3):155–160.
   PubMed Web of Science ®Google Scholar
• Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother. 1991 Jul;35(7):1273–1276.
   PubMed Web of Science ®Google Scholar
• Phuc Nguyen MC, Woerther PL, Bouvet M, et al. Escherichia coli as reservoir for macrolide resistance genes. Emerg Infect Dis. 2009 Oct;15(10):1648–1650.
   PubMed Web of Science ®Google Scholar
• Zhong P, Shortridge VD. The role of efflux in macrolide resistance. Drug Resist Updat. 2000 Dec;3(6):325–329.
   PubMed Web of Science ®Google Scholar
• Ojo KK, Ulep C, Van Kirk N, et al. The mef(A) gene predominates among seven macrolide resistance genes identified in gram-negative strains representing 13 genera, isolated from healthy portuguese children. Antimicrob Agents Chemother. 2004 Sep;48(9):3451–3456.
   PubMed Web of Science ®Google Scholar
• Roberts MC, Sutcliffe J, Courvalin P, et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999 Dec;43(12):2823–2830.
   PubMed Web of Science ®Google Scholar
• Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002 Feb 15;34(4):482–492.
   PubMed Web of Science ®Google Scholar
• Turnidge J. Susceptbility test methods: general considerations. In: Jorgensen J, Pfaller M, Carroll K, et al., editors. Manual of clinical microbiology. 11th ed. Washington (DC): ASM Press; 2015. p. 1246.
   Google Scholar
• Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007 Jul;20(3):391–408.
   PubMed Web of Science ®Google Scholar
• Hombach M, Bottger EC, Roos M. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines. Clin Microbiol Infect. 2013 Feb;19(2):E59–71.
   PubMed Web of Science ®Google Scholar
• Valsesia G, Roos M, Bottger EC, et al. A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing. J Clin Microbiol. 2015 Jun;53(6):1812–1822.
   PubMed Web of Science ®Google Scholar
• Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006 May;12(5):418–425.
   PubMed Web of Science ®Google Scholar
• Kahlmeter G. Defining antibiotic resistance-towards international harmonization. Ups J Med Sci. 2014 May;119(2):78–86.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing; Twenty-sixth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2016. (CLSI document M100-S26).
   Google Scholar
• The European committee on antimicrobial susceptibility testing [Internet]. Available from: http://www.eucast.org
   Google Scholar
• US Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Office of In Vitro Diagnostic Device (OIVD) Evaluation and Safety, Center for Devices and Radiological Health; 2009 [ [Internet]]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM388961.pdf
   Google Scholar
• Jorgensen J, Turnidge J. Susceptbility test methods: dilution and disk diffusion methods. In: Jorgensen J, Pfaller M, Carroll K, et al., editors. Manual of clinical microbiology. 11th ed. Washington (DC): ASM Press; 2015. p. 1253.
   Google Scholar
• Baker CN, Stocker SA, Culver DH, et al. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol. 1991 Mar;29(3):533–538.
   PubMed Web of Science ®Google Scholar
• Van Belkum A, Dunne WM Jr. Next-generation antimicrobial susceptibility testing. J Clin Microbiol. 2013 Jul;51(7):2018–2024.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Hindler JA. Emerging resistance, new antimicrobial agents … but no tests! the challenge of antimicrobial susceptibility testing in the current US regulatory landscape. Clin Infect Dis. 2016 Jul 1;63(1):83–88.
   PubMed Web of Science ®Google Scholar
• Karlowsky J, Richter S. Antimicrobial susceptibility testing systems. In: Jorgensen J, Pfaller M, Carroll K, et al., editors. Manuel of clinical microbiology. 11th ed. Washington (DC): ASM Press; 2015. p. 1274.
   Google Scholar
• Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001 Mar-Apr;7(2):333–336.
   PubMed Web of Science ®Google Scholar
• Kaur J, Chopra S, Sheevani, et al. Modified double disc synergy test to detect ESBL production in urinary isolates of escherichia coli and klebsiella pneumoniae. J Clin Diagn Res. 2013 Feb;7(2):229–233.
   PubMedGoogle Scholar
• Girlich D, Poirel L, Nordmann P. Value of the modified hodge test for detection of emerging carbapenemases in enterobacteriaceae. J Clin Microbiol. 2012 Feb;50(2):477–479.
   PubMed Web of Science ®Google Scholar
• Wang P, Chen S, Guo Y, et al. Occurrence of false positive results for the detection of carbapenemases in carbapenemase-negative escherichia coli and klebsiella pneumoniae isolates. PLoS One. 2011;6(10):e26356.
   PubMed Web of Science ®Google Scholar
• Pasteran F, Mendez T, Guerriero L, et al. Sensitive screening tests for suspected class A carbapenemase production in species of enterobacteriaceae. J Clin Microbiol. 2009 Jun;47(6):1631–1639.
   PubMed Web of Science ®Google Scholar
• Tijet N, Boyd D, Patel SN, et al. Evaluation of the carba NP test for rapid detection of carbapenemase-producing enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013 Sep;57(9):4578–4580.
   PubMedGoogle Scholar
• Mathers AJ, Carroll J, Sifri CD, et al. Modified hodge test versus indirect carbapenemase test: prospective evaluation of a phenotypic assay for detection of klebsiella pneumoniae carbapenemase (KPC) in enterobacteriaceae. J Clin Microbiol. 2013 Apr;51(4):1291–1293.
   PubMed Web of Science ®Google Scholar
• Pierce VM, Simner PJ, Lonsway DR, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among enterobacteriaceae. J Clin Microbiol. 2017 Aug;55(8):2321–2333.
   PubMed Web of Science ®Google Scholar
• Ledeboer NA, Hodinka RL. Molecular detection of resistance determinants. J Clin Microbiol. 2011 Sep;49(9 Suppl):S20–4.
   Google Scholar
• Abbott A, Fang F. Molecular detection of antibacterial drug resistance. In: Jorgensen J, Pfaller M, Carroll K, et al., editors. Manual of clinical microbiology. 11th ed. Washington (DC): ASM Press; 2015. p. 1379.
   Google Scholar
• Tato M, Ruiz-Garbajosa P, Traczewski M, et al. Multisite evaluation of cepheid xpert carba-R assay for detection of carbapenemase-producing organisms in rectal swabs. J Clin Microbiol. 2016 Jul;54(7):1814–1819.
   PubMed Web of Science ®Google Scholar
• McMullen AR, Yarbrough ML, Wallace MA, et al. Evaluation of genotypic and phenotypic methods to detect carbapenemase production in gram-negative bacilli. Clin Chem. 2017 Mar;63(3):723–730.
   PubMed Web of Science ®Google Scholar
• Tanner H. Verification of the cepheid xpert carba-R assay for the detection of carbapenemase genes in bacterial isolates cultured on alternative solid culture media. J Hosp Infect. 2017 Nov;97(3):254–257.
   PubMed Web of Science ®Google Scholar
• Moore NM, Canton R, Carretto E, et al. Rapid identification of five classes of carbapenem resistance genes directly from rectal swabs by use of the xpert carba-R assay. J Clin Microbiol. 2017 Jul;55(7):2268–2275.
   PubMed Web of Science ®Google Scholar
• Miller SA, Hindler JA, Chengcuenca A, et al. Use of ancillary carbapenemase tests to improve specificity of phenotypic definitions for carbapenemase-producing enterobacteriaceae. J Clin Microbiol. 2017 Jun;55(6):1827–1836.
   PubMed Web of Science ®Google Scholar
• Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol. 2016 Mar;54(3):687–698.
   PubMed Web of Science ®Google Scholar
• Dodemont M, De Mendonca R, Nonhoff C, et al. Performance of the verigene gram-negative blood culture assay for rapid detection of bacteria and resistance determinants. J Clin Microbiol. 2014 Aug;52(8):3085–3087.
   PubMed Web of Science ®Google Scholar
• Siu GK, Chen JH, Ng TK, et al. Performance evaluation of the verigene gram-positive and gram-negative blood culture test for direct identification of bacteria and their resistance determinants from positive blood cultures in hong kong. PLoS One. 2015 Oct 2;10(10):e0139728.
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Mezaki K, Kobayakawa M, et al. Impact of rapid identification of positive blood cultures using the verigene system on antibiotic prescriptions: A prospective study of community-onset bacteremia in a tertiary hospital in japan. PLoS One. 2017 Jul 24;12(7):e0181548.
   PubMed Web of Science ®Google Scholar
• Arroyo MA, Denys GA. Parallel evaluation of the MALDI sepsityper and verigene BC-GN assays for rapid identification of gram-negative bacilli from positive blood cultures. J Clin Microbiol. 2017 Sep;55(9):2708–2718.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kang GE, Kim HS, et al. Evaluation of verigene blood culture test systems for rapid identification of positive blood cultures. Biomed Res Int. 2016;2016:1081536.
   PubMed Web of Science ®Google Scholar
• Ward C, Stocker K, Begum J, et al. Performance evaluation of the verigene(R) (nanosphere) and FilmArray(R) (BioFire(R)) molecular assays for identification of causative organisms in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):487–496.
   PubMed Web of Science ®Google Scholar
• Ledeboer NA, Lopansri BK, Dhiman N, et al. Identification of gram-negative bacteria and genetic resistance determinants from positive blood culture broths by use of the verigene gram-negative blood culture multiplex microarray-based molecular assay. J Clin Microbiol. 2015 Aug;53(8):2460–2472.
   PubMed Web of Science ®Google Scholar
• Stoesser N, Batty EM, Eyre DW, et al. Predicting antimicrobial susceptibilities for escherichia coli and klebsiella pneumoniae isolates using whole genomic sequence data. J Antimicrob Chemother. 2013 Oct;68(10):2234–2244.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Pitout JD. Recent advances in the laboratory detection of carbapenemase-producing enterobacteriaceae. Expert Rev Mol Diagn. 2016 Jul;16(7):783–794.
   PubMed Web of Science ®Google Scholar
• Zankari E, Hasman H, Kaas RS, et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. J Antimicrob Chemother. 2013 Apr;68(4):771–777.
   PubMed Web of Science ®Google Scholar
• Shelburne SA, Kim J, Munita JM, et al. Whole-genome sequencing accurately identifies resistance to extended-spectrum beta-lactams for major gram-negative bacterial pathogens. Clin Infect Dis. 2017 Sep 1;65(5):738–745.
   PubMed Web of Science ®Google Scholar
• Ellington MJ, Ekelund O, Aarestrup FM, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST subcommittee. Clin Microbiol Infect. 2017 Jan;23(1):2–22.
   PubMed Web of Science ®Google Scholar
• Reuter S, Ellington MJ, Cartwright EJ, et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med. 2013 Aug 12;173(15):1397–1404.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: A novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013 Feb;73(2):159–177.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017 Aug 24;61(9). DOI:10.1128/AAC.00567-17
   Web of Science ®Google Scholar